BloggingStocks http://www.bloggingstocks.com BloggingStocks http://www.blogsmithmedia.com/http://www.bloggingstocks.com/media/feedlogo.gif BloggingStocks http://www.bloggingstocks.com en-us Copyright 2012 Weblogs, Inc. The contents of this feed are available for non-commercial use only. Blogsmith http://www.blogsmith.com/<![CDATA[Chasing Value: The NBA Should Learn from Others]]>http://www.bloggingstocks.com/2011/04/04/chasing-value-nba-should-learn-from-others/http://www.bloggingstocks.com/2011/04/04/chasing-value-nba-should-learn-from-others/http://www.bloggingstocks.com/2011/04/04/chasing-value-nba-should-learn-from-others/#commentsFiled under: , , , , , , ,

There have been many lessons to learn from the "Great Recession." But while the message is often clear, we can't always muster the courage, discipline or consensus to act on these lessons.

The National Basketball Association (NBA) is about to enter its second season -- the playoffs. And for a Laker fan in Los Angeles, there is much to look forward to. However, the current NBA collective bargaining agreement will end and we will have to witness another battle between the billionaires and the millionaires.

Why can't the NBA learn from other businesses that have successfully maneuvered through economic turmoil to achieve profitability?

Continue reading Chasing Value: The NBA Should Learn from Others

Chasing Value: The NBA Should Learn from Others originally appeared on BloggingStocks on Mon, 04 Apr 2011 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Chasing ValueDavid StearnFfeaturedFordGEgeneral electricJNJjohnson and johnsonkobe bryantLebron JamesNBANBA contract negotiationsNBA Lockout 2011nba playoffsPGprocter and gambleSheldon LiberMon, 04 Apr 2011 13:20:00 EST<![CDATA[Two Quarterly Reports: Electronic Arts and Pfizer]]>http://www.bloggingstocks.com/2011/02/01/two-quarterly-reports-electronic-arts-and-pfizer/http://www.bloggingstocks.com/2011/02/01/two-quarterly-reports-electronic-arts-and-pfizer/http://www.bloggingstocks.com/2011/02/01/two-quarterly-reports-electronic-arts-and-pfizer/#commentsFiled under: , , ,

I'm now going to take a brief look at two stocks that were affected by earnings releases earlier today. The two companies are a study in completely different business models: one sells video games, the other sells drugs. Then again, video games are a drug to some, so maybe they aren't so different?

First up: Electronic Arts (ERTS). EA wasn't exciting during the regular session. It closed up fractionally to $15.62; volume was strong, though. And after looking at the extended-hours reaction to the earnings report that was released following the ringing of the bell, it might be understandable why so many players were intent on getting in on the stock.

Continue reading Two Quarterly Reports: Electronic Arts and Pfizer

Two Quarterly Reports: Electronic Arts and Pfizer originally appeared on BloggingStocks on Tue, 01 Feb 2011 17:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>electronic artsElectronic Arts earningsERTSinthenewsJNJjohnson and johnsonPFEpfizerPfizer earningsTue, 01 Feb 2011 17:00:00 EST<![CDATA[The Timely 10: Best Blue Chip Dividend Buys]]>http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/http://www.bloggingstocks.com/2011/01/28/the-timely-10-iq-trends-best-blue-chip-buys/#commentsFiled under: , , , , , , , , , , , ,

AT&T logo"High-quality stocks bought at historically low-price-to-high-yield offer the best potential for downside protection and upside appreciation," says dividend specialist Kelley Wright.

The editor of IQ Trends explains, "Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.

"Our 'Timely Ten' list is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years. Do we believe that all 10 will go up simultaneously or immediately? Of course not.

Continue reading The Timely 10: Best Blue Chip Dividend Buys

The Timely 10: Best Blue Chip Dividend Buys originally appeared on BloggingStocks on Fri, 28 Jan 2011 10:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott Laboratoriesabtaltria groupattblue chip stockscoca-coladividend stocksEXCExelonfeaturedincome stocksinvestment quality trendsiq trendsjnjjohnson and johnsonkelley wrightkomomolson coorspepPepsicopgprocter and gamblesteven halperntapthestockadvisors.comunited technologiesutxyield stocksFri, 28 Jan 2011 10:00:00 EST<![CDATA[Johnson & Johnson Down on Q4 Report: Buying Opportunity?]]>http://www.bloggingstocks.com/2011/01/25/johnson-and-johnson-down-on-q4-report-buying-opportunity/http://www.bloggingstocks.com/2011/01/25/johnson-and-johnson-down-on-q4-report-buying-opportunity/http://www.bloggingstocks.com/2011/01/25/johnson-and-johnson-down-on-q4-report-buying-opportunity/#commentsFiled under: ,

Johnson & Johnson (JNJ) was down 1.8% to $61.07 at one point during afternoon trading. Volume was significant. The problem is the fourth-quarter earnings report. Was it so bad?

Well, it wasn't anything to gloat about. On a reported basis, profit dropped nine pennies to 70 cents per share, according to the Associated Press. On an adjusted basis, the profit figure was $1.03 per share, and that was in-line with Wall Street's projection.

Continue reading Johnson & Johnson Down on Q4 Report: Buying Opportunity?

Johnson & Johnson Down on Q4 Report: Buying Opportunity? originally appeared on BloggingStocks on Tue, 25 Jan 2011 15:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>inthenewsJNJjohnson and johnsonTue, 25 Jan 2011 15:00:00 EST<![CDATA[Chasing Value: 2011 Stock Picks -- Part 2]]>http://www.bloggingstocks.com/2010/12/27/chasing-value-2011-stock-picks-part-2/http://www.bloggingstocks.com/2010/12/27/chasing-value-2011-stock-picks-part-2/http://www.bloggingstocks.com/2010/12/27/chasing-value-2011-stock-picks-part-2/#commentsFiled under: , , , , , , , , , , , , , , , , , ,

Newcastle Investments (NCT) logoCould a stock that you made 1,100% on still have room to run? Yes, it is possible. In particular if it had a near death experience as a penny stock for a while.

That is the case with Newcastle Investments (NCT), the CMBS lender and real estate investment company that reached a recent high of $7.10 and has settled back down, most recently hovering between $6.70 to $7.00. It closed Thursday December 23 at $6.71.

Continue reading Chasing Value: 2011 Stock Picks -- Part 2

Chasing Value: 2011 Stock Picks -- Part 2 originally appeared on BloggingStocks on Mon, 27 Dec 2010 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>berkshire hathawayBRK.ABRK.BCChasingValueChevronChina Life InsuranceCitigroup Inc.DEODiageo plcEZCorp IncEZPWfeaturedGEgeneral electricJNJjohnson and johnsonLFCNCTNEnewcastle investmentNoble Corp.NovartisNVSoilRaytheon CompanyRDS.Aroyal dutch shellRTNTEFtelefonicaTEVATeva Pharmaceuticalswarren buffettMon, 27 Dec 2010 12:00:00 EST<![CDATA[Analyst Calls: AOL, FMCN, GT, HD, JNJ, JNS, LOW, QCOM, RY, UA, WAG ...]]>http://www.bloggingstocks.com/2010/12/09/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/12/09/analyst-upgrades-downgrades/http://www.bloggingstocks.com/2010/12/09/analyst-upgrades-downgrades/#commentsFiled under: , , , , , , , , , ,

Analyst Upgrades

  • Walgreen (WAG) and Triumph Group (TGI) to buy from neutral at UBS.
  • Focus Media (FMCN) to buy from neutral at Goldman.
  • Home Depot (HD) to outperform from market perform at FBR Capital.
  • Arbitron (ARB) to overweight from neutral at JPMorgan.
  • Waddell & Reed (WDR) and Legg Mason (LM) to overweight from equal weight, and Janus Capital (JNS) to overweight from underweight, at Barclays.
  • Central Euro Media (CETV) to buy from hold at Deutsche Bank.
  • GenOn Energy (GEN) and Ntelos (NTLS) to outperform from sector perform at RBC Capital.
  • Cooper Tire (CTB) to buy from neutral and Goodyear Tire (GT) to buy from underperform at BofA/Merrill.

Continue reading Analyst Calls: AOL, FMCN, GT, HD, JNJ, JNS, LOW, QCOM, RY, UA, WAG ...

Analyst Calls: AOL, FMCN, GT, HD, JNJ, JNS, LOW, QCOM, RY, UA, WAG ... originally appeared on BloggingStocks on Thu, 09 Dec 2010 12:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>analyst upgradesAOLARBArbitronCETVCNWCon-WayCooper TireCSFSCTBdowngradesFMCNFocus MediaGENHDHome DepotinitiationsinthenewsJanus CapitalJNJJNSJohnson and JohnsonLegg MasonLMLOWLowesNtelosNTLSPaychexPAYXPerkinElmerPKIPOWLQCOMQualcommRoyal Bank of CanadaRYTGITHITim HortonsUAUnder ArmourVistaprintVPRTWaddell and ReedWAGWalgreenWDRThu, 09 Dec 2010 12:00:00 EST<![CDATA[Chasing Value: 2011 Stock Picks -- The Journey Begins]]>http://www.bloggingstocks.com/2010/12/02/chasing-value-2011-stock-picks-the-journey-begins/http://www.bloggingstocks.com/2010/12/02/chasing-value-2011-stock-picks-the-journey-begins/http://www.bloggingstocks.com/2010/12/02/chasing-value-2011-stock-picks-the-journey-begins/#commentsFiled under: , , , , , , , , , , , , ,

Telefonica logoIt's that time of year when I start thinking about my 2011 stock picks, and enough folks have been nudging me that I might as well get on with it. The list will not be finalized until the end of the month. During the interim time I will take readers through a number of possibilities, explaining the rational for my suggestions along the way and adding and subtracting until I get the list down to ten.

Today I will start by reviewing opportunities discussed in another post and determine which of these stocks might provide the best value. The list was originally cast as a globally diversified, large cap, dividend paying and relatively stable group of companies that would likely weather any storm. See: Chasing Value: Bonds, Gold, Stocks and Capital Flight

Continue reading Chasing Value: 2011 Stock Picks -- The Journey Begins

Chasing Value: 2011 Stock Picks -- The Journey Begins originally appeared on BloggingStocks on Thu, 02 Dec 2010 15:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>AAPLAppleberkshire hathawayChasingValueChina Life InsuranceDEOdiageoEZCorp IncEZPWfeaturedGEGeneralElectriciPadiPhoneJNJjohnson and johnsonLFCNovartisNVSrds.aroyal dutch shellTevaTeva Pharmaceuticalsverizon wirelessVZWarrenBuffettThu, 02 Dec 2010 15:20:00 EST<![CDATA[Chasing Value: Bonds, Gold, Stocks and Capital Flight]]>http://www.bloggingstocks.com/2010/11/15/chasing-value-bonds-gold-stocks-and-capital-flight/http://www.bloggingstocks.com/2010/11/15/chasing-value-bonds-gold-stocks-and-capital-flight/http://www.bloggingstocks.com/2010/11/15/chasing-value-bonds-gold-stocks-and-capital-flight/#commentsFiled under: , , , , , , , , , , , , ,

up arrowIt certainly is presumptuous, perhaps even self serving of me to assume the market is going higher in the face of so much uncertainty.

The reason I hold this belief is that so much money is sitting on the sidelines and much of it is getting restless. It's one thing for those on a fixed income to suffer because the Federal Reserve is keeping interest rates so low, but it is quite another thing to expect $2 trillion dollars of corporate cash to want to live like senior citizens. That cash is a bigger drag on earnings with each passing day.

Continue reading Chasing Value: Bonds, Gold, Stocks and Capital Flight

Chasing Value: Bonds, Gold, Stocks and Capital Flight originally appeared on BloggingStocks on Mon, 15 Nov 2010 16:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>bonds vs stocksChasingValueChina Life InsurancedeflationDEODiageoFederal reserveGEgeneral electricGoldinflationJNJjohnson and johnsonLFCNovartis AGNVSRDS.Aroyal dutch shellTEFtelefonicaTEVATeva PharmaceuticalsUS TreasuriesMon, 15 Nov 2010 16:30:00 EST<![CDATA[Chasing Value: Cisco Shmisco -- It's Nothing]]>http://www.bloggingstocks.com/2010/11/11/chasing-value-cisco-shmisco-its-nothing/http://www.bloggingstocks.com/2010/11/11/chasing-value-cisco-shmisco-its-nothing/http://www.bloggingstocks.com/2010/11/11/chasing-value-cisco-shmisco-its-nothing/#commentsFiled under: , , , , , , ,

The market is down and the headlines are blaming Cisco Systems (CSCO), in part because they reported tepid earnings and somber growth projections. This once again underscores the fact that stock prices are always determined at the margins. Most folks could care less, and this is reflected by the big silent yawn of the majority of investors.

Cisco is not the bell-weather it has been in the past. Some of its business is down because there are more alternatives from competitors, "the cloud" keeps growing, and also many products have become commodities.

There are many other companies I would consider better measures of how the economy is doing.

Continue reading Chasing Value: Cisco Shmisco -- It's Nothing

Chasing Value: Cisco Shmisco -- It's Nothing originally appeared on BloggingStocks on Thu, 11 Nov 2010 14:30:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>ChasingValueCisco SystemsCSCOfeaturedGEgeneral electricJNJjohnson and johnsonMicrosoftMSFTPGprocter and gambleThu, 11 Nov 2010 14:30:00 EST<![CDATA[Johnson & Johnson (JNJ): World Class Buy]]>http://www.bloggingstocks.com/2010/11/09/johnson-and-johnson-jnj-world-class-buy/http://www.bloggingstocks.com/2010/11/09/johnson-and-johnson-jnj-world-class-buy/http://www.bloggingstocks.com/2010/11/09/johnson-and-johnson-jnj-world-class-buy/#commentsFiled under: , ,

Johnson & Johnson (JNJ) logo"Johnson & Johnson (JNJ) is an international giant, employing more than 115,000 people and operating in 60 countries," notes Gavin Graham.

The contributing analyst to Internet Wealth Builder explains, "The conservative stock is in a great business in an almost recession-proof field. Indeed, we see this an opportunity to buy a world-class stock at a reasonable price.

"It is a major provider of prescription drugs, including Remicade for arthritis and Procrit for red blood cell production.

Continue reading Johnson & Johnson (JNJ): World Class Buy

Johnson & Johnson (JNJ): World Class Buy originally appeared on BloggingStocks on Tue, 09 Nov 2010 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>drug stocksfeaturedgavin grahamgordon papeinternet wealth builderjnjjohnson and johnsonpharma stockspharmaceutical stockssteven halpernthestockadvisors.comTue, 09 Nov 2010 10:30:00 EST<![CDATA[Johnson & Johnson Reports Q3 Numbers]]>http://www.bloggingstocks.com/2010/10/19/johnson-and-johnson-reports-q3-numbers/http://www.bloggingstocks.com/2010/10/19/johnson-and-johnson-reports-q3-numbers/http://www.bloggingstocks.com/2010/10/19/johnson-and-johnson-reports-q3-numbers/#commentsFiled under: ,

Johnson & Johnson (JNJ) logoJohnson & Johnson (JNJ) has had its problems in recent times with recalls, but when you think about the stock, you can't help thinking that it's one of those blue-chip winners that will be around for a long time. It's a name that you can utilize a dollar-cost-averaging strategy with in an attempt to keep the cost basis at an attractive level.

Today, the health-care concern issued its third-quarter report. While the top line failed to do much, as this article indicates, the bottom line was able to top the analyst community's prediction. Net income came in at $1.23 per share, eight pennies ahead of the estimate. A weaker dollar did act as a partial driver of the profit performance.

Continue reading Johnson & Johnson Reports Q3 Numbers

Johnson & Johnson Reports Q3 Numbers originally appeared on BloggingStocks on Tue, 19 Oct 2010 17:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>dividend investingdividend stocksDividendsinthenewsJNJjohnson and johnsonTue, 19 Oct 2010 17:00:00 EST<![CDATA[Johnson & Johnson Sets Sites on Crucell: What Would This Mean for Stock?]]>http://www.bloggingstocks.com/2010/09/17/johnson-and-johnson-sets-sites-on-crucell/http://www.bloggingstocks.com/2010/09/17/johnson-and-johnson-sets-sites-on-crucell/http://www.bloggingstocks.com/2010/09/17/johnson-and-johnson-sets-sites-on-crucell/#commentsFiled under: , ,

Early Friday, American health care giant Johnson & Johnson (JNJ) announced that it is in "advanced talks" to acquire Dutch biotech firm Crucell NV. According to the report, the deal (which would help strengthen JNJ's vaccine business) is going to cost $2.29 billion. JNJ already owns a 17.9% stake in Crucell and will be offering €24.75 in cash for the remaining 82%. The offer price represents a 58% premium from Crucell's Thursday close.

In a joint statement, the companies noted expectations for "Crucell's strength in the manufacture, discovery and commercialization of vaccines would create a strong platform for Johnson & Johnson in the vaccine market." According to the Associated Press, JNJ has roughly $64 billion in annual sales and is the "world's biggest and most broadly based health care company."

Continue reading Johnson & Johnson Sets Sites on Crucell: What Would This Mean for Stock?

Johnson & Johnson Sets Sites on Crucell: What Would This Mean for Stock? originally appeared on BloggingStocks on Fri, 17 Sep 2010 08:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>acquisitionCrucellfeaturedhealth careJNJjohnson and johnsonFri, 17 Sep 2010 08:30:00 EST<![CDATA[Should You Avoid Medtronic?]]>http://www.bloggingstocks.com/2010/08/27/should-you-avoid-medtronic/http://www.bloggingstocks.com/2010/08/27/should-you-avoid-medtronic/http://www.bloggingstocks.com/2010/08/27/should-you-avoid-medtronic/#commentsFiled under: , ,

Medical technology company Medtronic (MDT), whose colleagues include Boston Scientific (BSX) and Johnson & Johnson (JNJ), has not had a good year. The chart communicates a very bearish situation. But when a stock takes a significant dip, many investors wonder if it is time to buy.

Earlier in the week, the business reported disappointing fiscal first-quarter news. If that wasn't enough, UBS issued a downgrade on the shares. The firm has reduced the equity's status to neutral from buy, according to BloggingStocks' analyst calls article. The price target is $33. Medtronic finished Thursday's session at a quote of $32.28.

Continue reading Should You Avoid Medtronic?

Should You Avoid Medtronic? originally appeared on BloggingStocks on Fri, 27 Aug 2010 09:00:00 EST. Please see our terms for use of feeds.

Read | Permalink | Email this | Comments]]>boston scientificBSXfeaturedJNJjohnson and johnsonMDTMedtronicFri, 27 Aug 2010 09:00:00 EST<![CDATA[Johnson & Johnson Recalling Contact Lenses in Asia and Europe]]>http://www.bloggingstocks.com/2010/08/24/johnson-and-johnson-recalling-contact-lenses-in-asia-and-europe/http://www.bloggingstocks.com/2010/08/24/johnson-and-johnson-recalling-contact-lenses-in-asia-and-europe/http://www.bloggingstocks.com/2010/08/24/johnson-and-johnson-recalling-contact-lenses-in-asia-and-europe/#commentsFiled under: ,

Johnson & Johnson (JNJ) logoJohnson & Johnson (JNJ) announced Monday that it is recalling 1-Day Acuvue contact lenses sold mainly in Japan and other countries in Asia and Europe. None of the recalled contact lenses were sold in the U.S. or in Canada.

The company said that it received a "limited number" of complaints from Japanese customers of unusual stinging or pain when inserting the Acuvue lenses. The recall started on August 18 and was not immediately announced in the U.S.

Continue reading Johnson & Johnson Recalling Contact Lenses in Asia and Europe

Johnson & Johnson Recalling Contact Lenses in Asia and Europe originally appeared on BloggingStocks on Tue, 24 Aug 2010 10:15:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>contact lensescontactsinthenewsJohnson and Johnsonproduct recallrecallTue, 24 Aug 2010 10:15:00 EST<![CDATA[Chasing Value: Granny Said, 'It Has Turned into One Big Casino']]>http://www.bloggingstocks.com/2010/08/16/chasing-value-granny-said-it-has-turned-into-one-big-casino/http://www.bloggingstocks.com/2010/08/16/chasing-value-granny-said-it-has-turned-into-one-big-casino/http://www.bloggingstocks.com/2010/08/16/chasing-value-granny-said-it-has-turned-into-one-big-casino/#commentsFiled under: , , , , , , , , , , , , , , , , ,

Here is a common sentiment about the stock market: "No fun at all. As I have said before, I believe it has turned into one big casino largely divorced from its original goal of providing capital to companies who produce something of value."

There's a lot of truth to what "granny" recently said to me in an e-mail. Fortunately she also noted "FYI Granny's up 5.86% + dividends." That would give her a gain of about 10% in the past ten months since I posted Where should granny put $50,000, suggesting a very conservative portfolio for an uncertain time.

Not only has she earned a very nice return, surpassing her CD account by 9.5% (20 fold), but she was able to do so with a great deal less volatility than the overall market most of us have lived through.

Continue reading Chasing Value: Granny Said, 'It Has Turned into One Big Casino'

Chasing Value: Granny Said, 'It Has Turned into One Big Casino' originally appeared on BloggingStocks on Mon, 16 Aug 2010 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>ADPAltriaAnnalyCapitalManagementautomatic data processingChasingValueDEOdiageoDUKDuke Energyfeaturedgeneral millsIBM Corp.international business machinesJNJjohnson and johnsonKelloggMCDmcdonaldsMerckMOMRKNLYNovartisNVSPGprocter and gambleSOSouthernCompanyMon, 16 Aug 2010 13:30:00 EST<![CDATA[Chasing Value: Shocked By Toxic Stock and Still Finding Deals]]>http://www.bloggingstocks.com/2010/07/20/chasing-value-shocked-by-toxic-stock-and-still-finding-deals/http://www.bloggingstocks.com/2010/07/20/chasing-value-shocked-by-toxic-stock-and-still-finding-deals/http://www.bloggingstocks.com/2010/07/20/chasing-value-shocked-by-toxic-stock-and-still-finding-deals/#commentsFiled under: , , , , , , , , , , ,

Yesterday I was shocked by the response to a poll I conducted in this very same column where I suggested that six out-of-favor stocks were a buy and would out perform the over all market. The results left me puzzled for several reasons.

For one thing I have been blogging for Aol. for over four years and I cannot remember an occasion that there was so much unanimity on anything before. I expected approximately equal votes for each of four possible responses to my question, and an appreciable number that might think I was off my rocker. Instead, I was jolted to a new reality when 84% of the respondents agreed that the six toxic stocks would outperform.

The six stocks are Bank of America (BAC), Citigroup (C), General Electric (GE), BP p.l.c. (BP), Goldman Sachs (GS) and Transocean (RIG). I thought I was taking a contrarian position and based on recent market activity that would seem to be the case. This raises another question. If my readers are any reflection of the market, how could the market move in the opposite direction of such overwhelming sentiment?

Continue reading Chasing Value: Shocked By Toxic Stock and Still Finding Deals

Chasing Value: Shocked By Toxic Stock and Still Finding Deals originally appeared on BloggingStocks on Tue, 20 Jul 2010 15:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>BACBank of AmericabpCChasing ValuecitigroupEbixfeaturedGEgeneral electricGoldman SachsGSibmJNJjohnson and johnsonrig of the daySheldon LibertransoceanTue, 20 Jul 2010 15:00:00 EST<![CDATA[Johnson & Johnson Reports In-Line Second-Quarter Earnings]]>http://www.bloggingstocks.com/2010/07/20/johnson-and-johnson-second-quarter-earnings/http://www.bloggingstocks.com/2010/07/20/johnson-and-johnson-second-quarter-earnings/http://www.bloggingstocks.com/2010/07/20/johnson-and-johnson-second-quarter-earnings/#commentsFiled under: ,

Johnson & Johnson (JNJ) reported second-quarter net earnings and diluted earnings per share of $3.4 billion and $1.23, respectively. Taking an after-tax gain of $67 million out of the equation (stemming from the net impact of "litigation matters"), the company earned $1.21 per share and $3.4 billion. The consensus estimate called for earnings of $1.21 per share and revenue of $15.69 billion.

Quarterly revenue checked in at $15.33 billion. In addition, JNJ revised its full-year estimate, now expecting adjusted earnings between $4.65 and $4.75 per share. This new range includes the impact of the recalls of some OTC medicines, the suspension of production at a plant in Pennsylvania, and poor foreign-exchange rates.

Continue reading Johnson & Johnson Reports In-Line Second-Quarter Earnings

Johnson & Johnson Reports In-Line Second-Quarter Earnings originally appeared on BloggingStocks on Tue, 20 Jul 2010 10:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>consumer goodsearningsfeaturedJNJJohnson and Johnsontechnical analysisTue, 20 Jul 2010 10:30:00 EST<![CDATA[Blue Chip Buys: The Timely Ten]]>http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/http://www.bloggingstocks.com/2010/07/14/blue-chip-buys-the-timely-ten/#commentsKelley Wright.

The editor of Investment Quality Trends explains, "To that end we believe that high-quality stocks purchased at historically low-price-to-high-yield offers the best potential for downside protection and upside appreciation.

"The Timely Ten list of stocks is our reasoned expectation based on our methodology and experience for what we believe will perform best over the next five years.

Continue reading Blue Chip Buys: The Timely Ten

Blue Chip Buys: The Timely Ten originally appeared on BloggingStocks on Wed, 14 Jul 2010 13:20:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>Abbott Laboratoriesabtadpautomatic data processingblue chip stockscoca-colacvxdividendsExxonMobilincome stocksinvestment quality trendsiq trendsjnjjohnson and johnsonkomcdmcdonaldspeppgpmprocter and gamblesteven halpernthestockadvisors.comxomyield stocksWed, 14 Jul 2010 13:20:00 EST<![CDATA[Goldman Sachs Targets Allergan as Takeover Candidate]]>http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/http://www.bloggingstocks.com/2010/07/13/goldman-sachs-targets-allergan-as-takeover-candidate/#commentsFiled under: , ,

If you're interested on taking a bet on a potential high-flyer, you might want to take a look at Allergan (AGN).

Goldman Sachs recently said they expect more M&A activity in pharmaceutical and that Allergan is a prime candidate for a takeover. Sanofi-Aventis (SNY) and Eli Lilly & Co. (LLY) are two companies analysts are speculating may be interested in acquiring Allergan.

Goldman also upgraded its price target for Allergan on its Conviction Buy List from $78 to $81.

Continue reading Goldman Sachs Targets Allergan as Takeover Candidate

Goldman Sachs Targets Allergan as Takeover Candidate originally appeared on BloggingStocks on Tue, 13 Jul 2010 13:30:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>aclagnalconallerganEli LillyfeaturedGoldman Sachsjnjjohnson and johnsonllySanofi-AventissnyTue, 13 Jul 2010 13:30:00 EST<![CDATA[ADHD Patch Helps Investors Focus on Shire]]>http://www.bloggingstocks.com/2010/07/07/adhd-patch-helps-investors-focus-on-shire/http://www.bloggingstocks.com/2010/07/07/adhd-patch-helps-investors-focus-on-shire/http://www.bloggingstocks.com/2010/07/07/adhd-patch-helps-investors-focus-on-shire/#commentsFiled under:

ShireThe Food and Drug Administration (FDA) recently gave Shire Plc (SHPGY) shareholders something to smile about when it approved Daytrana for treating patients between 13 and 17 years who suffer from Attention Deficit Hyperactivity Disorder (ADHD).

Daytrana is the only ADHD treatment that is available in a transdermal patch, which delivers methylphenidate through the skin into the bloodstream. It is already approved for use by patients between 6 and 12 years.

With this announcement, Shire -- which licensed Daytrana from Noven Pharmaceuticals -- stands to gain market share and increase revenues.

Continue reading ADHD Patch Helps Investors Focus on Shire

ADHD Patch Helps Investors Focus on Shire originally appeared on BloggingStocks on Wed, 07 Jul 2010 18:00:00 EST. Please see our terms for use of feeds.

Permalink | Email this | Comments]]>adhdADHD drugsdaytranafdafood and drug administrationgenzgenzymeinthenewsjnjjohnson and johnsonNovartisnvsshireshpgyWed, 07 Jul 2010 18:00:00 EST